Horizons in Nutritional Science

Metabolomics: an emerging post-genomic tool for nutrition

Phillip D. Whitfield[1]*, Alexander J. German[2] and Peter-John M. Noble[2]

[1]*Department of Veterinary Preclinical Sciences and*
[2]*Small Animal Teaching Hospital, Faculty of Veterinary Science, University of Liverpool, Crown Street, Liverpool L69 7ZJ, UK*

The post-genomic era has been driven by the development of technologies that allow the function of cells and whole organisms to be explored at the molecular level. Metabolomics is concerned with the measurement of global sets of low-molecular-weight metabolites. Metabolite profiles of body fluids or tissues can be regarded as important indicators of physiological or pathological states. Such profiles may provide a more comprehensive view of cellular control mechanisms in man and animals, and raise the possibility of identifying surrogate markers of disease. Metabolomic approaches use analytical techniques such as NMR spectroscopy and MS to measure populations of low-molecular-weight metabolites in biological samples. Advanced statistical and bioinformatic tools are then employed to maximise the recovery of information and interpret the large datasets that are generated. Metabolomics has already been used to study toxicological mechanisms and disease processes and offers enormous potential as a means of investigating the complex relationship between nutrition and metabolism. Examples include the metabolism of dietary substrates, drug-induced disturbances of lipid metabolites in type 2 diabetes mellitus and the therapeutic effects of vitamin supplementation in the treatment of chronic metabolic disorders.

Metabolomics: Metabonomics: Metabolite profiling

With the advent of the post-genomic era, biological, medical and veterinary research has witnessed an explosion in strategies that provide an integrative view of the molecular regulation of cells and whole organisms (Watkins & German, 2002). These advances have been driven by the development of novel technologies that can analyse global sets of gene products. Transcriptomics defines the population of mRNA species in a cell at a specific time and set of conditions; proteomics addresses the challenging problem of defining changes in protein expression, protein dynamics and post-translational modifications; whilst the emerging field of metabolomics measures changes in populations of low-molecular-weight metabolites under a given set of conditions (Fiehn *et al.* 2001).

Low-molecular-weight metabolites represent the endproducts of cell regulatory processes and as such advertise the response of biological systems to a variety of genetic and environmental influences (Fiehn, 2002). Metabolomic strategies aim to detect changes in the distribution and concentration of a broad range of metabolites and can be applied to multiple levels of biological organisation from single cells to whole organisms. These analyses involve the use of modern analytical techniques to measure global populations of metabolites in biological samples. Advanced statistical and bioinformatic tools are then employed to maximise the recovery of information and to aid interpretation of the very large datasets that are generated.

In man and animals, metabolite profiles can be regarded as important indicators of normal phenotype and pathology, and offer the possibility of identifying surrogate biomarkers of disease states. Abnormal cellular processes may lead to disturbances in the profile of endogenous low-molecular-weight metabolites. Metabolomic-based strategies can, therefore, provide an insight into metabolite perbutations caused by differential gene expression, toxicological insult, pathophysiological processes and altered nutritional status (Nicholson *et al.* 2002). The present article will review the emerging post-genomic science of metabolomics. Metabolomic-based technologies will be outlined and a number of applications of metabolomic analyses described. The implications of metabolomics for the nutritional sciences will also be discussed.

Terminology

The field of metabolomics has already produced a vast array of specialist terms; however, their precise definitions are still evolving. The greatest debate relates to the terms

---

used to describe the global measurement of low-molecular-weight molecules in biological systems; metabolomics and metabonomics. Metabolomics has been defined as the comprehensive analysis of the whole metabolome under a given set of conditions (Goodacre *et al.* 2004). Metabonomics has been described as the quantitative measurement of time-related multiparametric metabolic responses of multicellular systems to pathophysiological stimuli or genetic modification (Nicholson *et al.* 1999). It has recently been suggested that metabolomics should be used as a parallel term to genomics, transcriptomics and proteomics, and that a more appropriate term for metabonomics would be metabolic fingerprinting (Fiehn, 2002; Sumner *et al.* 2003). Clearly, some research will overlap these definitions and a consensus on nomenclature needs to be established within the field. A list of terms and definitions is given in Table 1.

Metabolomic technologies

A major goal of all metabolite-profiling strategies is to examine large populations of low-molecular-weight metabolites within a biological system. Since body fluids such as plasma and urine contain hundreds of small molecules and there may be as many as 200 000 metabolites in the plant kingdom (Fiehn, 2002), this represents a considerable analytical challenge. Unlike genomics, transcriptomics and, in theory, proteomics, where essentially just one class of compound is analysed, metabolomic strategies have to detect a broad spectrum of molecules with diverse properties (Weckwerth, 2003).

Conventional methods for the analysis of low-molecular-weight metabolites have focused on specific compound classes, with isolation and detection protocols being tailored to the chemical and physical characteristics of the metabolites of interest. This approach has been widely employed to profile the metabolites that accumulate in the body fluids and tissues of patients with inborn errors of metabolism such as aminoacidopathies, fatty acid oxidation defects and organic acidaemias (Clayton, 2001; Rashed, 2001). In contrast, metabolomic analyses must avoid bias for specific molecules and ideally should be able to detect every individual metabolite. Achieving the broadest overview of metabolite composition is difficult and requires an integrated strategy for metabolite analysis and data processing.

Suitable analytical techniques for the global analysis of metabolites must be sensitive, robust and have the capacity for high-throughput analysis required to screen large numbers of samples. In recent years, considerable advances have been made in the development of analytical technologies to measure and interpret complex metabolite profiles. However, given the wide dynamic and chemical range of low-molecular-weight metabolites in biological mixtures, it is not yet possible to analyse all low-molecular-weight metabolites with a single analytical platform (Glassbrook & Ryals, 2001). The techniques most frequently employed for metabolomic studies are NMR spectroscopy and MS.

The data acquired by either NMR spectroscopy or MS from biological mixtures produce a complex spectral profile which reflects the metabolic status of the organism (Shockcor & Holmes, 2002). A single spectrum can contain thousands of signals. In order to interpret the biochemical perturbations, metabolomic-based strategies employ powerful bioinformatic and statistical methods (Fig. 1).

Nuclear magnetic resonance spectroscopy

To date, NMR spectroscopy has been the major analytical technique used to profile global populations of low-molecular-weight metabolites. This use of NMR spectroscopy in metabolomic studies has been pioneered by Nicholson and colleagues (Nicholson *et al.* 1999, 2002; Nicholson & Wilson, 2003).

NMR-based analysis of biological samples has significant advantages for metabolomic applications. NMR spectroscopy requires little or no sample preparation and, as it is non-destructive, is capable of generating a comprehensive profile of low-molecular-weight metabolites from intact biofluids and tissues (Reo, 2002). NMR spectroscopy is also inherently quantitative. Despite these considerable advantages, NMR does suffer from certain drawbacks. NMR is not as sensitive as MS and requires relatively large sample volumes. The issue of sensitivity has been addressed by the development of magnets with increased field strength and improvements in the design of NMR detectors (Griffin, 2004); however, the analysis of low-abundance metabolites by NMR spectroscopy can still prove problematic.

Mass spectrometry

The high sensitivity of MS combined with its wide dynamic range makes the technique an extremely powerful tool for the analysis of large populations of metabolites.

Table 1. Terminology of metabolomics

| Term	Definition
Metabolomics	The comprehensive analysis of the whole metabolome under a given set of conditions (Goodacre *et al.* 2004)
Metabonomics	The quantitative measurement of time-related multiparametric metabolic responses of multicellular systems to pathophysiological stimuli or genetic modification (Nicholson *et al.* 1999)
Metabolome	The full set of low-molecular-weight metabolites within, or that can be secreted by, a given cell type or tissue (Nicholson & Wilson, 2003)
Metabolic fingerprinting	The application of any technological approach whose output is processed with pattern-recognition software and without differentiation of individual metabolites (Sumner *et al.* 2003)
Lipidomics	The characterisation of chemically distinct lipid species in cells and the molecular mechanisms through which they facilitate cellular function (Han & Gross, 2003)

Fig. 1. Overview of experimental strategies for the profiling of low-molecular-weight metabolites in biological systems. Metabolomics-based approaches use sophisticated analytical techniques such as NMR spectroscopy and MS to measure populations of low-molecular-weight metabolites in biofluids or tissues. Statistical methods, for example principal component analysis, are then employed to maximise the recovery of information and interpret the large datasets that are generated.

However, as with NMR spectroscopy, MS has a number of weaknesses. Mass spectrometric analyses require extensive sample preparation. Low-molecular-weight metabolites from biological samples typically have to be extracted in organic solvents, which can result in losses of certain compounds. Furthermore, variable ionisation efficiencies of metabolites mean that MS is unable to provide absolute quantification (Weckwerth & Fiehn, 2002), although the concentrations of low-molecular-weight metabolites can be accurately determined by MS using stable-isotope internal standards.

Ion suppression and matrix effects can also lead to difficulties in detecting certain compounds. These problems can be alleviated by coupling a chromatography system to the mass spectrometer. The chromatographic step is able to reduce the number of competing analytes entering the mass spectrometer in addition to separating complex mixtures of metabolites (Pham-Tuan *et al.* 2003). As a result, liquid chromatography–MS is increasingly being used to profile low-molecular-weight metabolites (Plumb *et al.* 2002,

2003; Idborg-Bjorkman *et al.* 2003). Similarly, GC–MS has been widely employed for metabolomic applications, despite the need to chemically derivatise many biological compounds before analysis (Fiehn *et al.* 2000*a,b*; Jonsson *et al.* 2004; Weckwerth *et al.* 2004). The recent developments in Fourier transform ion cyclotron resonance MS have also aroused interest within the field of metabolomics. The capability of Fourier transform ion cyclotron resonance MS to generate spectral data relating to the elemental composition of metabolites suggests that this analytical technique may play a major role in future metabolomic strategies (Aharoni *et al.* 2002).

Statistical analysis

The profiling of global sets of low-molecular-weight metabolites in biological samples generates a wealth of information relating to the physiological or pathophysiological status of an organism (Shockcor & Holmes, 2002). To provide evidence of metabolite perbutations, pattern-recognition tools are employed. These statistical methods provide an efficient, non-biased procedure for interpreting the complex, multivariate datasets and allow the correlation of metabolic responses in biological systems to be fully investigated (Holmes & Antti, 2002).

Pattern-recognition methods fall into two general classes; supervised and unsupervised. Unsupervised methods, such as principal component analysis, determine pattern sets according to their properties and without prior knowledge of the sample class. These approaches are typically employed to identify clustering within sample populations. Supervised methods are more powerful statistical tools that use additional information on the datasets, such as clinical data, to determine similarities and differences between predefined groups. An example of a supervised method is partial least squares data analysis (Holmes & Antti, 2002; Lindon *et al.* 2003*a*).

Identification of low-molecular-weight metabolites

The identification of metabolites in biological systems can lead to the targeting of specific metabolic pathways which may provide greater insight into the mechanisms of certain metabolic disturbances. However, the bioinformatic tools required to deconvolute spectral data and identify low-molecular-weight metabolites are still being developed (Mendes, 2002; Kell, 2004). Investigators in the fields of genomics and proteomics can access databases such as Genbank or Swiss-Prot to rapidly determine the identity of a gene or protein, but there is currently no equivalent database for metabolomic analyses. Whilst there are some spectral libraries available for the comparison of NMR or MS data, the structure of low-molecular-weight metabolites must largely be determined manually, which is a time-consuming process.

Applications of metabolomics

Whilst still in its infancy, metabolomics is already beginning to make a significant impact in the fields of biology

and medicine. This section provides an outline of the major applications arising from strategies which aim to screen global populations of low-molecular-weight metabolites.

Gene function

Metabolite profiling techniques have been used to explore the function of genes in plants, yeast and experimental animals. In one such study, the metabolite profiles of leaf extracts from *Arabidopsis thaliana* were examined. Analysis of wild-type and transgenic plants demonstrated that the individual plant types each had a distinct metabolite profile (Fiehn *et al.* 2000*a*). These findings suggest a potential use for metabolomics in the monitoring of genetically modified foods (Kuiper *et al.* 2001; Roessner *et al.* 2001; Sumner *et al.* 2003; Trethewey, 2004).

Metabolomic strategies have also been used to define gene function in the yeast, *Saccharomyces cerevisiae*. Raamsdonk *et al.* (2001) employed NMR spectroscopy to characterise the phenotype of silent mutations of specific genes. In addition, investigators have employed MS-based metabolomic strategies to obtain a 'metabolic footprint' of extracellular metabolites derived from *S. cerevisiae* (Allen *et al.* 2003). This study was able to distinguish between the wild-type and mutant strains of yeast during different growth phases.

Another investigation characterised the urinary metabolite profiles from two phenotypically normal strains of mice (Gavaghan *et al.* 2000). Using NMR spectroscopy and pattern-recognition methods, differences were observed in tricarboxylic acid cycle intermediates and methylamine pathway between the strains of mice. This technology has obvious potential in evaluating animal models of human disease states and further demonstrates the capability of metabolomics in determining the metabolic signature of complex living organisms.

Toxicology and drug discovery

A major application of metabolite profiling is in the field of toxicology where it provides a means of rapidly assessing the health risks of specific toxins. This strategy has been used to determine the disturbances in metabolite populations of body fluids and tissues following the administration of various chemicals and drugs to experimental animals (Beckwith-Hall *et al.* 1998; Nicholls *et al.* 2001; Waters *et al.* 2002; Lenz *et al.* 2004).

The Consortium for Metabonomic Toxicology (COMET) is using metabolite-profiling methods to evaluate the safety of candidate drugs (Lindon *et al.* 2003*b*). This group, which comprises Imperial College of Science Technology and Medicine, London (UK) and five major pharmaceutical companies (Bristol-Myers-Squibb, Eli Lily and Company, Hoffman-LaRoche, NovoNordisk and Pfizer Incorporated), is employing NMR spectroscopy in conjunction with multivariate statistical analysis, to screen the urine and serum of laboratory rodents for markers of hepatic and renal toxicity. This experimental approach promises to play a central role in improving the drug discovery process through faster and better assessments of drug efficacy and toxicity.

Disease mechanisms and diagnosis

A number of complex diseases, such as atherosclerosis, type 2 diabetes mellitus and cancer, may result from a chronic imbalance of normal metabolism. Therefore, metabolomic-based approaches may be of use in identifying surrogate biomarkers of pathological states. The ability to clinically evaluate diseases using biochemical parameters has major implications for diagnostic procedures, prognostic evaluation and the monitoring of treatments.

A groundbreaking study used NMR-based methods to identify individuals with CHD (Brindle *et al.* 2002). By characterising metabolite disturbances in serum, individuals with CHD could be differentiated from patients with angiographically normal coronary arteries. This approach was also employed to examine the disease-related metabolic fingerprints of osteoarthritic guinea-pigs (Lamers *et al.* 2003). Analyses showed significant disturbances in the urinary concentrations of lactic acid, malic acid, hypoxanthine and alanine in affected animals, indicating possible metabolic pathways which may be involved in the osteoarthritic process.

A similar experimental strategy was used to explore the molecular pathogenesis of a specific form of cancer. Griffiths & Stubbs (2002, 2003) employed NMR spectroscopy to measure metabolite changes in mouse-derived tumour cells that were deficient in the transcription factor, hypoxia-inducible factor-1 (HIF-1). HIF-1 up regulates the genes of certain glycolytic enzymes and the glucose transporters GLUT-1 and GLUT-3. The absence of this messenger is known to slow tumour growth. Data analysis showed that ATP production was significantly impaired in HIF-1-deficient tumour cells. Interestingly, the cells also had lower concentrations of glycine, betaine and various choline metabolites. These metabolic intermediates are used in the *de novo* synthesis of purines. The findings indicate that the primary function of HIF-induced up regulation of glycolysis and glucose transport in tumours is to provide an increased supply of precursors for the production of high-energy phosphates. These studies demonstrate the potential of metabolomics to characterise disease mechanisms.

Finally, a study has used metabolomic strategies to profile the metabolite disturbances in the *mnd* mouse model of Batten's disease (Griffin *et al.* 2002). Batten's disease belongs to a group of lysosomal storage disorders know as the neuronal ceroid lipofuscinoses which are characterised by progressive neurodegeneration. Metabolomic-based analyses demonstrated altered metabolite profiles in the neural tissues and sera of *mnd* mice compared with control animals. Free radical damage to brain tissues is thought to play a role in the pathogenesis of neuronal ceroid lipofuscinoses and the *mnd* mouse model has a profound deficiency of vitamin E, a key physiological antioxidant. As a result, the investigators examined the therapeutic effects of dietary supplementation with vitamin E. Metabolomic approaches were able to show that the treatment reversed some of the metabolic disturbances associated with the disease state.

Metabolomics and nutrition

The arrival of the post-genomic era has enabled researchers to investigate the effects of nutrients on physiological functions in man and animals at the molecular level (Elliott & Ong, 2002; Ordovas & Mooser, 2004; van Ommen, 2004). The influence of nutrition in the development of disease is widely understood and it is well known that chronic diseases can have both dietary and genetic components (Go *et al.* 2003; Milner, 2003). Metabolomics is uniquely suited to explore the complex relationship between nutrition and metabolism and to investigate the role that dietary components play in health and disease (Watkins *et al.* 2001).

In addition, metabolomics has the potential to explore homeostatic control and how this metabolic balance may be disturbed by deficiencies or excesses of dietary components (German *et al.* 2003b). The potential value of metabolomics to nutrition has already been demonstrated in studies which have examined the metabolism of ethyl glucoside (Teague *et al.* 2004) and isoflavones (Solanky *et al.* 2003) found in the diet.

Investigators have also begun utilising metabolomic-based strategies to analyse broad classes of endogenous metabolites and in particular, lipids. Lipids are amongst the most heavily studied molecules within the nutritional sciences. They play a central role in many physiological processes and their concentrations are often disturbed in metabolic diseases (German *et al.* 2003a). In recognition of the importance of lipids in cellular metabolism the National Institute of General Medical Sciences in the USA recently funded a US $35 million project entitled 'Lipid Metabolites and Pathway Strategy' (Lipid MAPS; www.lipidmaps.org). This research programme aims to fully characterise the lipid populations and signalling pathways in the mouse macrophage.

The global analysis of lipid classes has been termed 'lipidomics' (Han & Gross, 2003). Lipidomics-based analyses have already been used to examine the effects of the perioxisome proliferator-activated receptor-γ agonist, rosiglitazone, in a murine model of type 2 diabetes mellitus (Watkins *et al.* 2002). This study revealed that the administration of this drug had a wide range of effects on lipids in the body fluids and tissues of the treated mice. Rosiglitazone lowered the lipid concentrations of plasma, significantly altered cardiolipin metabolism in the heart, and led to an unusual profile of PUFA in adipose tissue.

A similar study recently employed lipidomics to explore the changes in lipid metabolism of cultured 3T3-L1 adipocytes (Su *et al.* 2004). The investigations demonstrated that following differentiation, there was a substantial accumulation of odd-chain fatty acids in all of the major lipid classes of the fat cells, including triacylglycerols and phospholipids. The findings suggest an important role for peroxisomes in the processing of adipocyte fatty acids.

Conclusions and future perspectives

Metabolomics is an emerging post-genomic science that is already being employed to investigate gene function, toxicological mechanisms and the pathogenesis of disease states. Metabolomics now promises to play a major role in the nutritional sciences. However, despite the considerable advances in this field, huge challenges still remain. Metabolite-profiling strategies, in many respects, only provide a 'snapshot' of the metabolic status of a cell, tissue or organism. Metabolism is a dynamic process and strategies for determining the turnover of low-molecular-weight metabolites will provide further insight into the complexities of metabolic mechanisms (Hellerstein, 2003, 2004). Improved technologies for metabolite analysis and better computational tools for data handling will, therefore, need to be established if metabolomics is to realise its full potential. It is highly probable that the field of metabolomics will continue to be driven by technological developments for the foreseeable future.

References

Aharoni A, Ric de Vos CH, Verhoeven HA, Maliepaard CA, Kruppa G, Bino R & Goodenowe DB (2002) Non-targeted metabolome analysis by use of Fourier transform ion cyclotron mass spectrometry. *OMICS* **6**, 217–234.

Allen J, Davey HM, Broadhurst D, Heald JK, Rowland JJ, Oliver SG & Kell DB (2003) High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. *Nat Biotechnol* **21**, 692–696.

Beckwith-Hall BM, Nicholson JK, Nicholls A, Nicholls AW, Foxall PJ, Lindon JC, Connor SC, Abdi M, Connelly J & Holmes E (1998) Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three hepatotoxins. *Chem Res Toxicol* **11**, 260–272.

Brindle JT, Antti H, Holmes E, *et al.* (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using ¹H-NMR-based metabonomics. *Nat Med* **8**, 1439–1444.

Clayton PT (2001) Applications of mass spectrometry in the study of inborn errors of metabolism. *J Inherit Metab Dis* **24**, 139–150.

Elliott R & Ong TJ (2002) Nutritional genomics. *BMJ* **324**, 1438–1442.

Fiehn O (2002) Metabolomics – the link between genotypes and phenotypes. *Plant Mol Biol* **48**, 155–171.

Fiehn O, Kloska S & Altmannn T (2001) Integrated studies on plant biology using multiparallel techniques. *Curr Opin Biotechnol* **12**, 82–86.

Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN & Willmitzer L (2000a) Metabolite profiling for plant functional genomics. *Nat Biotechnol* **18**, 1157–1161.

Fiehn O, Kopka J, Trethewey RN & Willmitzer L (2000b) Identification of uncommon plant metabolites based on calculation of elemental compositions using gas chromatography and quadrupole mass spectrometry. *Anal Chem* **72**, 3573–3580.

Gavaghan CL, Holmes E, Lenz E, Wilson ID & Nicholson JK (2000) An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences:

application to the C57BL10J and Alpk: ApfCD mouse. *FEBS Lett* **484**, 169–174.

German JB, Roberts MA & Watkins SM (2003*a*) Genomics and metabolomics as markers for the interaction of diet and health: lessons from lipids. *J Nutr* **133**, 2078S–2083S.

German JB, Roberts MA & Watkins SM (2003*b*) Personal metabolomics as a next generation nutritional assessment. *J Nutr* **133**, 4260–4266.

Glassbrook N & Ryals J (2001) A systemic approach to biochemical profiling. *Curr Opin Plant Biol* **4**, 186–190.

Go VL, Butrum RR & Wong DA (2003) Diet, nutrition and cancer prevention: the postgenomic era. *J Nutr* **133**, 3830S–3836S.

Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG & Kell DB (2004) Metabolomics by numbers: acquiring and understanding global metabolite data. *Trends Biotechnol* **22**, 245–252.

Griffin JL (2004) Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. *Curr Opin Chem Biol* **7**, 648–654.

Griffin JL, Muller D, Woograsingh R, Jowatt V, Hindmarsh A, Nicholson JK & Martin JE (2002) Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics. *Physiol Genomics* **11**, 195–203.

Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL & Stubbs M (2002) Metabolic changes detected by *in vivo* magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1β (HIF-1β): evidence of an anabolic role for the HIF-1 pathway. *Cancer Res* **62**, 688–695.

Griffiths JR & Stubbs M (2003) Opportunities for studying cancer by metabolomics: preliminary observations on tumors deficient in hypoxia-inducible factor 1. *Adv Enzyme Regul* **43**, 67–76.

Han X & Gross RW (2003) Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. *J Lipid Res* **44**, 1071–1079.

Hellerstein MK (2003) In vivo measurement of fluxes through metabolic pathways: the missing link in functional genomics and pharmaceutical research. *Annu Rev Nutr* **23**, 379–402.

Hellerstein MK (2004) New stable isotope-mass spectrometric techniques for measuring fluxes through intact metabolic pathways in mammalian systems: introduction of moving pictures into functional genomics and biochemical phenotyping. *Metab Eng* **6**, 85–100.

Holmes E & Antti H (2002) Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. *Analyst* **127**, 1549–1557.

Idborg-Bjorkman H, Edlund PO, Kvalheim OM, Schuppe-Koistinen I & Jacobsson SP (2003) Screening of biomarkers in rat urine using LC/electrospray ionisation-MS and two-way data analysis. *Anal Chem* **75**, 4784–4792.

Jonsson P, Gullberg J, Nordstrom A, Kusano M, Kowalczyk M, Sjostrom M & Moritz T (2004) A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MS. *Anal Chem* **76**, 1738–1745.

Kell DB (2004) Metabolomics and systems biology: making sense of the soup. *Curr Opin Microbiol* **7**, 296–307.

Kuiper HA, Kleter GA, Noteborn HP & Kok EJ (2001) Assessment of the food safety issues relating to genetically modified foods. *Plant J* **27**, 503–528.

Lamers RJ, DeGroot J, Spies-Faber EJ, *et al.* (2003) Identification of disease- and nutrient-related metabolic fingerprints in osteoarthritic guinea pigs. *J Nutr* **133**, 1776–1780.

Lenz EM, Bright J, Knight R, Wilson ID & Major H (2004)

Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. *J Pharm Biomed Anal* **35**, 599–608.

Lindon JC, Holmes E & Nicholson JK (2003*a*) So what's the deal with metabonomics? *Anal Chem* **75**, 384A–391A.

Lindon JC, Nicholson JK, Holmes E, *et al.* (2003*b*) The role of metabonomics in toxicology and its evaluation by the COMET project. *Toxicol Appl Pharmacol* **187**, 137–146.

Mendes P (2002) Emerging bioinformatics for the metabolome. *Brief Bioinform* **3**, 134–145.

Milner JA (2003) Incorporating basic nutrition science into health interventions for cancer prevention. *J Nutr* **133**, 3820S–3826S.

Nicholls AW, Holmes E, Lindon JC, Shockcor JP, Farrant RD, Haselden JN, Damment SJ, Waterfield CJ & Nicholson JK (2001) Metabonomic investigations into hydrazine toxicity in the rat. *Chem Res Toxicol* **14**, 975–987.

Nicholson JK, Connelly J, Lindon JC & Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. *Nat Rev Drug Discov* **1**, 153–161.

Nicholson JK, Lindon JC & Holmes E (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica* **29**, 1181–1189.

Nicholson JK & Wilson ID (2003) Understanding 'global' systems biology: metabonomics and the continuum of metabolism. *Nat Rev Drug Discov* **2**, 668–676.

Ordovas JM & Mooser V (2004) Nutrigenomics and nutrigenetics. *Curr Opin Lipidol* **15**, 101–108.

Pham-Tuan H, Kashavelis L, Daykin CA & Janssen HG (2003) Method development in high-performance liquid chromatography for high throughput profiling and metabonomic studies of biofluid samples. *J Chromatogr* **789B**, 283–301.

Plumb RS, Stumpf CL, Gorenstein MV, Castro-Perez JM, Dear GJ, Anthony M, Sweatman BC, Connor SC & Haselden JN (2002) Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. *Rapid Commun Mass Spectrom* **16**, 1991–1996.

Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN & Dear GJ (2003) Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. *Rapid Commun Mass Spectrom* **17**, 2632–2638.

Raamsdonk LM, Teusink B, Broadhurst D, *et al.* (2001) A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. *Nat Biotechnol* **19**, 45–50.

Rashed MS (2001) Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. *J Chromatogr* **758B** 27–48.

Reo NV (2002) NMR-based metabolomics. *Drug Chem Toxicol* **25**, 375–382.

Roessner U, Luedemann A, Brust D, Fiehn O, Linke T, Willmitzer L & Fernie A (2001) Metabolite profiling allows comprehensive phenotyping of genetically or environmentally modified plant systems. *Plant Cell* **13**, 11–29.

Shockcor JP & Holmes E (2002) Metabonomic applications in toxicity screening and disease diagnosis. *Curr Top Med Chem* **2**, 35–51.

Solanky KS, Bailey NJ, Beckwith-Hall BM, Davis A, Bingham S, Holmes E, Nicholson JK & Cassidy A (2003) Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. *Anal Biochem* **323**, 197–204.

Su X, Han X, Yang J, Mancuso DJ, Chen J, Bickel PE & Gross RW (2004) Sequential ordered fatty acid α oxidation and Δ9 desaturation are major determinants of lipid storage and utilization in differentiating adipocytes. *Biochemistry* **43**, 5033–5044.

Sumner LW, Mendes P & Dixon RA (2003) Plant metabolomics: large-scale phytochemistry in the functional genomics era. *Phytochemistry* **62**, 817–836.

Teague C, Holmes E, Maibaum E, Nicholson J, Tang H, Chan Q, Elliott P & Wilson I (2004) Ethyl glucoside in human urine following dietary exposure: detection by ^{1}H NMR spectroscopy as a result of metabonomic screening in humans. *Analyst* **129**, 259–264.

Trethewey RN (2004) Metabolite profiling as an aid to metabolic engineering in plants. *Curr Opin Plant Biol* **7**, 196–201.

van Ommen B (2004) Nutrigenomics: exploiting systems biology in the nutrition and health area. *Nutrition* **20**, 4–8.

Waters NJ, Holmes E, Waterfield CJ, Farrant RD & Nicholson JK (2002) NMR and pattern recognition studies on liver extracts and in livers from rats treated with alpha-naphthylisothiocyanate. *Biochem Pharmacol* **64**, 67–77.

Watkins SM & German JB (2002) Toward the implantation of metabolomic assessments of human health and nutrition. *Curr Opin Biotechnol* **13**, 512–516.

Watkins SM, Hammock BD, Newman JW & German JB (2001) Individual metabolism should guide agriculture towards foods for improved health and nutrition. *Am J Clin Nutr* **74**, 283–286.

Watkins SM, Reifsnyder PR, Pan HJ, German JB & Leiter EH (2002) Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. *J Lipid Res* **43**, 1809–1817.

Weckwerth W (2003) Metabolomics in systems biology. *Annu Rev Plant Biol* **54**, 669–689.

Weckwerth W & Fiehn O (2002) Can we discover novel pathways using metabolomic analysis? *Curr Opin Biotechnol* **13**, 156–160.

Weckwerth W, Loureiro ME, Wenzel K & Fiehn O (2004) Differential metabolic networks unravel the effects of silent plant phenotypes. *Proc Natl Acad Sci USA* **101**, 7809–7814.